New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - prothioconazole - emulsifiable concentrate - prothioconazole 250 g/litre - fungicide - fungicide

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - flucloxacillin, quantity: 500 mg - capsule, hard - excipient ingredients: brilliant blue fcf; erythrosine; magnesium stearate; gelatin; sodium lauryl sulfate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - flucloxacillin, quantity: 250 mg - capsule, hard - excipient ingredients: titanium dioxide; erythrosine; brilliant blue fcf; gelatin; magnesium stearate; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis. changes made as described in the letter of 30/4/1998 from jason borg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 545 mg (equivalent: flucloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: povidone; titanium dioxide; purified talc; brilliant blue fcf; iron oxide red; magnesium stearate; iron oxide yellow; gelatin; microcrystalline cellulose; sodium starch glycollate - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 272.5 mg (equivalent: flucloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: povidone; brilliant blue fcf; magnesium stearate; sodium starch glycollate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; microcrystalline cellulose; gelatin - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 545 mg (equivalent: flucloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: povidone; titanium dioxide; purified talc; brilliant blue fcf; iron oxide red; magnesium stearate; iron oxide yellow; gelatin; microcrystalline cellulose; sodium starch glycollate - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 272.5 mg (equivalent: flucloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: povidone; brilliant blue fcf; magnesium stearate; sodium starch glycollate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; microcrystalline cellulose; gelatin - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow - sical is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. sical a is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. sical is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: butylated hydroxyanisole; iron oxide red; purified water; gelatin; iron oxide yellow; fractionated coconut oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxytoluene - calciprox is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calciprox is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calciprox is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.